BRIEF-Hikma Pharma maintains 20 pct revenue growth target

LONDON Fri Nov 2, 2012 3:09am EDT

Related Topics

LONDON Nov 2 (Reuters) - Hikma Pharmaceuticals PLC : * Pleased to maintain our guidance for 2012 of around 20% group revenue growth * Continue to expect around 20% branded revenue growth for the full year * Global injectables business has been performing ahead of our expectations * Saw an initial pick up in our generics business in the beginning of the

second half

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.